Log in

Start Your Membership Now

February 16, 2011 This report, by Ernst & Young Global Life Sciences Center, outlines how pharmaceutical companies are implementing consumer-focused IT strategies. Additionally, the authors sought to depict an operational shift in the pharmacy industry that they referred to as “Pharma 3.0.” They described Pharma 3.0 as focused on consumer health outcomes, and driven by both technology advances and a need to develop sustainable health care systems; in contrast to Pharma 1.0 in which pharmaceutical firms focused on developing blockbuster drugs and Pharma 2.0 (the current operational model), which is focused on diversification and cost . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Market Intelligence Resource | February 16, 2011

Global Pharmacy Industry Report 2011; Progressions Building Pharma 3.0

February 16, 2011 This report, by Ernst & Young Global Life Sciences Center, outlines how pharmaceutical companies are implementing consumer-focused IT strategies. Additionally, the authors sought to depict an operational shift in the pharmacy industry that they referred to as “Pharma 3.0.” They described Pharma 3.0 as focused on consumer health outcomes, and driven by both technology advances and a need to develop sustainable health care systems; in contrast to Pharma 1.0 in which pharmaceutical firms focused on developing blockbuster drugs and Pharma 2.0 (the current operational model), which is focused on diversification and cost . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.